Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion

Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi Ophthalmology Department, Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan Purpose: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) sec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tagami M, Sai R, Fukuda M, Azumi A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	branch retinal vein occlusion (BRVO) macular edema ranibizumab aflibercept Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2838509e83ec4734a6b5377d804ede3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2838509e83ec4734a6b5377d804ede3d
record_format	dspace
spelling	oai:doaj.org-article:2838509e83ec4734a6b5377d804ede3d2021-12-02T00:38:29ZProlongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion1177-5483https://doaj.org/article/2838509e83ec4734a6b5377d804ede3d2017-02-01T00:00:00Zhttps://www.dovepress.com/prolongation-of-injection-interval-after-switching-therapy-from-ranibi-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi Ophthalmology Department, Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan Purpose: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in daily practice. Materials and methods: This retrospective study enrolled 15 eyes in 15 Japanese patients with ME secondary to BRVO who had been receiving a pro re nata regimen of ranibizumab and had provided written informed consent to switch to aflibercept therapy. The intravitreal injection interval, central retinal thickness, and visual acuity were evaluated before and after switching. Results: The mean period of ranibizumab treatment was 11.8±4.2 months. The mean observation period after switching to aflibercept was 10.6±3.4 months, and seven patients were observed for more than 12 months after switching. The mean intravitreal injection interval was prolonged by 23.6 days with aflibercept (68.2±26.4 days with ranibizumab vs 91.8±33.2 days with aflibercept; P=0.0011). The mean intravitreal injection interval just before the switch was 81.3±35.6 days and was significantly prolonged to 100.8±34.2 days just after the switch to aflibercept (P=0.0309). The mean central retinal thickness did not change before or after the switch to aflibercept (295±55 µm with ranibizumab vs 276±25 µm with aflibercept; P=0.12). The mean visual acuity also remained at an improved level after the switch. No systemic or ocular side effects were evident during the study period. Conclusion: Switching therapy from ranibizumab to aflibercept in Japanese patients with ME secondary to BRVO prolonged the intravitreal injection interval without anatomical or functional degradation. Keywords: branch retinal vein occlusion, macular edema, ranibizumab, afliberceptTagami MSai RFukuda MAzumi ADove Medical Pressarticlebranch retinal vein occlusion (BRVO)macular edemaranibizumabafliberceptOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 403-408 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	branch retinal vein occlusion (BRVO) macular edema ranibizumab aflibercept Ophthalmology RE1-994
spellingShingle	branch retinal vein occlusion (BRVO) macular edema ranibizumab aflibercept Ophthalmology RE1-994 Tagami M Sai R Fukuda M Azumi A Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
description	Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi Ophthalmology Department, Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan Purpose: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in daily practice. Materials and methods: This retrospective study enrolled 15 eyes in 15 Japanese patients with ME secondary to BRVO who had been receiving a pro re nata regimen of ranibizumab and had provided written informed consent to switch to aflibercept therapy. The intravitreal injection interval, central retinal thickness, and visual acuity were evaluated before and after switching. Results: The mean period of ranibizumab treatment was 11.8±4.2 months. The mean observation period after switching to aflibercept was 10.6±3.4 months, and seven patients were observed for more than 12 months after switching. The mean intravitreal injection interval was prolonged by 23.6 days with aflibercept (68.2±26.4 days with ranibizumab vs 91.8±33.2 days with aflibercept; P=0.0011). The mean intravitreal injection interval just before the switch was 81.3±35.6 days and was significantly prolonged to 100.8±34.2 days just after the switch to aflibercept (P=0.0309). The mean central retinal thickness did not change before or after the switch to aflibercept (295±55 µm with ranibizumab vs 276±25 µm with aflibercept; P=0.12). The mean visual acuity also remained at an improved level after the switch. No systemic or ocular side effects were evident during the study period. Conclusion: Switching therapy from ranibizumab to aflibercept in Japanese patients with ME secondary to BRVO prolonged the intravitreal injection interval without anatomical or functional degradation. Keywords: branch retinal vein occlusion, macular edema, ranibizumab, aflibercept
format	article
author	Tagami M Sai R Fukuda M Azumi A
author_facet	Tagami M Sai R Fukuda M Azumi A
author_sort	Tagami M
title	Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
title_short	Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
title_full	Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
title_fullStr	Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
title_full_unstemmed	Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
title_sort	prolongation of injection interval after switching therapy from ranibizumab to aflibercept in japanese patients with macular edema secondary to branch retinal vein occlusion
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/2838509e83ec4734a6b5377d804ede3d
work_keys_str_mv	AT tagamim prolongationofinjectionintervalafterswitchingtherapyfromranibizumabtoafliberceptinjapanesepatientswithmacularedemasecondarytobranchretinalveinocclusion AT sair prolongationofinjectionintervalafterswitchingtherapyfromranibizumabtoafliberceptinjapanesepatientswithmacularedemasecondarytobranchretinalveinocclusion AT fukudam prolongationofinjectionintervalafterswitchingtherapyfromranibizumabtoafliberceptinjapanesepatientswithmacularedemasecondarytobranchretinalveinocclusion AT azumia prolongationofinjectionintervalafterswitchingtherapyfromranibizumabtoafliberceptinjapanesepatientswithmacularedemasecondarytobranchretinalveinocclusion
_version_	1718403543716593664

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion

Ejemplares similares